scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1112395364 |
P356 | DOI | 10.1186/S40478-019-0679-5 |
P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/s40478-019-0679-5 |
P932 | PMC publication ID | 6391792 |
P698 | PubMed publication ID | 30808409 |
P50 | author | John Q. Trojanowski | Q6253636 |
Hannah J Brown | Q89158989 | ||
P2093 | author name string | Bin Zhang | |
Virginia M Y Lee | |||
Ian McGeary | |||
Michael X Henderson | |||
Modupe F Olufemi | |||
Medha Sengupta | |||
P2860 | cites work | Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 |
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies | Q24653247 | ||
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies | Q27686837 | ||
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
Alpha-synuclein in Lewy bodies | Q27860680 | ||
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases | Q28119192 | ||
Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 | ||
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease | Q29614762 | ||
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin | Q29620478 | ||
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice | Q29620597 | ||
Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. | Q34330786 | ||
Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). | Q35045422 | ||
Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates. | Q35215169 | ||
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death | Q35484581 | ||
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization | Q36780383 | ||
A novel α-synuclein missense mutation in Parkinson disease | Q36841475 | ||
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? | Q36925651 | ||
Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs | Q37308940 | ||
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction | Q37376010 | ||
Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells | Q37446544 | ||
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. | Q38832432 | ||
Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease | Q39686532 | ||
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model | Q41539639 | ||
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. | Q46777308 | ||
Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology | Q47338060 | ||
LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network | Q47362838 | ||
Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation | Q48192270 | ||
Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations | Q48252778 | ||
Lewy body diseases and multiple system atrophy as alpha-synucleinopathies | Q48326536 | ||
PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. | Q50145319 | ||
The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. | Q55265334 | ||
LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis | Q58745072 | ||
LRRK2 activation in idiopathic Parkinson's disease. | Q60143544 | ||
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease | Q80794093 | ||
Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology | Q87710261 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Synuclein | Q24767155 |
MLI-2 | Q27225595 | ||
P304 | page(s) | 28 | |
P577 | publication date | 2019-02-26 | |
P1433 | published in | Acta Neuropathologica Communications | Q27724912 |
P1476 | title | LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice | |
P478 | volume | 7 |
Q96304526 | "LRRK2: Autophagy and Lysosomal Activity" |
Q89611946 | Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease |
Q89484985 | An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts |
Q92534986 | Autophagy and LRRK2 in the Aging Brain |
Q89720803 | Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein |
Q98177378 | LRRK2 and Protein Aggregation in Parkinson's Disease: Insights From Animal Models |
Q92933189 | LRRK2 in Parkinson disease: challenges of clinical trials |
Q96219413 | Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous Lrrk2 mutations and ameliorated by Lrrk2 genetic knock-out |
Q99716681 | Pathogenic LRRK2 requires secondary factors to induce cellular toxicity |
Q92186851 | Spread of α-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis |
Search more.